Global Healthcare Conference in London

16-19 November 2026 | The Waldorf Hilton
#JefferiesHealthcare

Jefferies looks forward to bringing together our partners and more than 800 leading global public and private companies across the biotechnology, pharmaceuticals, medical technology, and healthcare services sectors.

icon-handshake

This year’s gathering marks the seventeenth anniversary of Europe’s largest healthcare-dedicated conference, reinforcing its position as a premier conference for industry leaders.

icon-meeting

The conference addresses near and long-term investment opportunities and examines the trends shaping healthcare in the U.S. and globally, providing actionable insights for companies and investors.

2025 Conference Highlights

By the numbers

800+

Healthcare Companies

4,100

Attendees

9,500

Institutional Investor Meetings

15,000+

Total Meetings

Jefferies is proud to partner with London Life Sciences Week, anchored by the Jefferies Global Healthcare Conference. This collaboration underscores our shared commitment to strengthening London’s position as a global hub for life sciences innovation and investment.

Networking Event Guide

In partnership with London Life Sciences Week, Catalyst Advisors, and Optimum Strategic Communications, we invite you to join the mailing list for the official networking event guide.

Thank You to Our 2026 Sponsors

  • Healthcare
    September 2025
    $2,000,000,000
    Sale to Lotus Pharmaceutical
    Joint Financial Advisor
  • Healthcare
    April 2025
    Undisclosed
    Sale to KKR
    Joint Financial Advisor
  • Healthcare
    July 2025
    Undisclosed
    Majority Sale to EQT
    Sole Financial Advisor
  • Healthcare
    July 2025
    Undisclosed
    Investment by Bain Capital, Kohlberg and Mubadala Investment Company
    Lead Financial Advisor
  • Healthcare
    December 2024
    Undisclosed
    Acquisition of Synthon
    Joint Financial Advisor
  • Healthcare
    August 2025
    $750,000,000
    Convertible notes offering
    Joint Bookrunner
  • Healthcare
    March 2025
    $2,200,000,000
    Sale to and Subsequent Merger with Advanced Instruments
    Sole Financial Advisor
  • Healthcare
    September 2025
    $8,000,000,000
    Sale to Genmab
    Sole Financial Advisor
  • Healthcare
    August 2025
    Undisclosed
    Sale to CapVest
    Joint Lead Financial Advisor
  • Healthcare
    June 2025
    $9,500,000,000
    Sale to Sanofi
    Lead Financial Advisor
  • Healthcare
    January 2025
    $14,630,000,000
    Sale to Johnson & Johnson
    Joint Financial Advisor
  • Healthcare
    November 2025
    $259,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $316,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $288,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $150,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $120,000,000
    Private Placement of Equity
    Lead Placement Agent
  • Healthcare
    September 2025
    $288,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    September 2025
    $144,000,000
    Convertible Notes Offering
    Lead Left Bookrunner
  • Healthcare
    June 2025
    $230,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    June 2025
    $230,000,000
    Common Stock Offering
    Joint Bookrunner
  • Healthcare
    June 2025
    $345,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    April 2025
    $300,000,000
    PIPE in support of reverse merger with Aerovate Therapeutics
    Lead Placement Agent
  • Healthcare
    March 2025
    $500,000,000
    Common Stock Offering
    Joint Bookrunner
  • Healthcare
    January 2025
    $403,000,000
    Common Stock Offering
    Joint Bookrunner
  • Healthcare
    December 2024
    $250,000,000
    Private Placement of Equity
    Lead Placement Agent
  • Healthcare
    October 2025
    €808,000,000
    Initial Public Offering
    Joint Bookrunner
  • Healthcare
    January 2025
    Undisclosed
    Acquisition of Medical Media Business from FUJIFILM Irvine Scientific
    Sole Financial Advisor
  • Healthcare
    January 2025
    Undisclosed
    Investment from TA Associates and Novo Holdings
    Sole Financial Advisor
  • Healthcare
    April 2025
    Undisclosed
    Sale of stake to Hellman & Friedman
    Joint Financial Advisor
  • Healthcare
    March 2025
    €250,000,000
    Preferred Equity Investment from Carlyle
    Sole Financial Advisor
  • Healthcare
    February 2025
    €404,000,000
    Initial Public Offering
    Joint Global Coordinator and
    Joint Bookrunner